The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer

被引:46
|
作者
Abbaoui, Besma [1 ,7 ]
Telu, Kelly H. [2 ]
Lucas, Christopher R. [1 ,8 ]
Thomas-Ahner, Jennifer M. [3 ]
Schwartz, Steven J. [3 ,4 ]
Clinton, Steven K. [3 ,5 ]
Freitas, Michael A. [3 ,6 ]
Mortazavi, Amir [3 ,5 ]
机构
[1] Ohio State Univ, Coll Med, Integrated Biomed Sci, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Arts & Sci, Dept Chem, Columbus, OH 43210 USA
[3] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[4] Ohio State Univ, Coll Food Agr & Environm Sci, Dept Food Sci & Technol, Columbus, OH 43210 USA
[5] Ohio State Univ, Coll Med, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
[6] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA
[7] Parker Food Sci & Technology Bldg,2015 Fyffe Rd, Columbus, OH 43210 USA
[8] N350 Scott Lab, 201W 19th Ave Columbus, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
Cruciferous vegetables; Broccoli; Bladder cancer; Isothiocyanates; Sulforaphane; Erucin; Histone acetylation; Histone phosphorylation; DEACETYLASE INHIBITORS; SULFORAPHANE RETARDS; CURRENT PERSPECTIVES; H1; PHOSPHORYLATION; GENE-EXPRESSION; HDAC INHIBITORS; IN-VITRO; APOPTOSIS; CELLS; EPIGENETICS;
D O I
10.1016/j.jprot.2017.01.013
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cruciferous vegetable intake is associated with reduced risk of bladder cancer, yet mechanisms remain unclear. Cruciferous vegetable isothiocyanates (ITCs), namely sulforaphane (SFN) and erucin (ECN), significantly inhibit histone deacetylase (HDAC) activity in human bladder cancer cells representing superficial to invasive biology (59-83% inhibition with 20 AM, 48 h treatment), and in bladder cancer xenografts (59 +/- 3% ECN inhibition). Individual HDACs inhibited by SFN and ECN include HDACs 1, 2, 4 and 6. Interestingly, global acetylation status of histories H3 or H4 remain unaltered. The interplay between HDAC inhibition and modest modulation of AcH3 and AcH4 status is partially explained by decreased histone acetyl transferase activity (48.8 +/- 5.3%). In contrast, a significant decrease in phosphorylation status of all isoforms of histone H1 was observed, concomitant with increased phosphatase PP1f3 and PP2A activity. Together, these findings suggest that ITCs modulate histone status via HDAC inhibition and phosphatase enhancement. This allows for reduced levels of histone H1 phosphorylation, a marker correlated with human bladder cancer progression. Therefore, ITC-mediated inhibition of histone H1 phosphorylation presents a novel direction of research in elucidating epidemiological relationships and supports future food-based prevention strategies. Significance: Collectively, our findings suggest that the cruciferous vegetable isothiocyanates: sulforaphane (SFN) and erucin (ECN), impact histones status in bladder cancer cells by modulating specific HDACs and HATs, and enhancing phosphatase activity, resulting in reduction of historic H1 phosphorylation. These findings are significant due to the fact that our previous work positively correlated historic H1 phosphorylation with bladder cancer carcinogenesis and progression. Therefore, we propose that SFN and ECN may inhibit bladder carcinogenesis via epigenetic modulation of gene expression associated with histone H1 phosphorylation. These efforts may elucidate biomarkers useful in epidemiologic studies related to cruciferous vegetable intake and cancer risk or provide intermediate biomarkers for food-based clinical intervention studies in high-risk cohorts. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:94 / 103
页数:10
相关论文
共 50 条
  • [41] Cross talk between histone 3 acetylation, methylation and phosphorylation by intermittent hypoxia
    Nanduri, Jayasri
    Wang, Ning
    Prabhakar, Nanduri
    PHYSIOLOGY, 2023, 38
  • [42] PHOSPHORYLATION, METHYLATION AND ACETYLATION OF HISTONE H3 BY ETHANOL: CHARACTERISTICS AND MECHANISMS
    Aroor, A. R.
    Shukla, S. D.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2010, 34 (08) : 48A - 48A
  • [43] Radiosensitization by histone deacetylase inhibition is independent of tumor histone acetylation status in experimental colorectal cancer models
    Folkvord, Sigurd
    Ree, Anne H.
    Furre, Torbjorn
    Halvorsen, Thomas
    Flatmark, Kjersti
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3582S - 3582S
  • [44] BET (bromodomain and extra-terminal) histone acetylation readers and histone acetylation in hypoxia adaptation in triple-negative breast cancer
    da Motta, Leonardo L.
    Slater, Charlotte
    Vancauwenberghe, Eric
    Potgieter, Tammy
    Masterson, Mitchell
    Heery, David M.
    McIntyre, Alan
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 548 - 548
  • [45] The clinical application of targeting cancer through histone acetylation and hypomethylation
    Gilbert, J
    Gore, SD
    Herman, JG
    Carducci, MA
    CLINICAL CANCER RESEARCH, 2004, 10 (14) : 4589 - 4596
  • [46] Histone acetylation: a key determinant of acquired cisplatin resistance in cancer
    Natu, Abhiram
    Verma, Tripti
    Khade, Bharat
    Thorat, Rahul
    Gera, Poonam
    Dhara, Sangita
    Gupta, Sanjay
    CLINICAL EPIGENETICS, 2024, 16 (01)
  • [47] Inhibition of core histone acetylation by the cancer preventive peptide lunasin
    Jeong, Hyung Jin
    Jeong, Jin Boo
    Kim, Dae Seop
    de Lumen, Ben O.
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2007, 55 (03) : 632 - 637
  • [48] Histone acetylation and chromatin signature in stem cell identity and cancer
    Shukla, Vivek
    Vaissiere, Thomas
    Herceg, Zdenko
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2008, 637 (1-2) : 1 - 15
  • [49] Barcelona conference on epigenetics and cancer: 50 years of histone acetylation
    Perez-Salvia, Montserrat
    Simo-Riudalbas, Laia
    Ausio, Juan
    Esteller, Manel
    EPIGENETICS, 2015, 10 (05) : 446 - 451
  • [50] Histone acetylation: a key determinant of acquired cisplatin resistance in cancer
    Abhiram Natu
    Tripti Verma
    Bharat Khade
    Rahul Thorat
    Poonam Gera
    Sangita Dhara
    Sanjay Gupta
    Clinical Epigenetics, 16